New oral treatment for hyperkalaemia

Veltassa (patiromer) is a powder for oral suspension licensed for the treatment of hyperkalaemia in adults.

Patiromer is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol complex as a counterion. The drug increases faecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen resulting in reduced serum potassium.

Each Veltassa sachet contains 8.4g or 16.8g patiromer (as sorbitex calcium) to be mixed with approximately 80ml water, apple or cranberry juice. The mixture should be taken within one hour of initial suspension.

The product information for Veltassa states that there is limited experience in patients with serum potassium concentrations greater than 6.5mmol/l and in those with end-stage renal disease (eGFR <15ml/min/1.73m2) or on dialysis.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...